TScan Therapeutics (TCRX) Gains from Investment Securities (2023 - 2025)

TScan Therapeutics (TCRX) has reported Gains from Investment Securities for 3 consecutive years, with -$55000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Gains from Investment Securities rose 96.45% year-over-year to -$55000.0 in Q4 2025; TTM through Dec 2025 was -$2.4 million, a 38.18% increase from a year earlier, with the FY2025 full-year figure at -$2.4 million, up 38.18% from the prior year.
• Gains from Investment Securities was -$55000.0 for Q4 2025 at TScan Therapeutics, up from -$291000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at -$55000.0 in Q4 2025 and troughed at -$1.5 million in Q4 2024.
• A 3-year average of -$793666.7 and a median of -$786000.0 in 2025 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 96.45% in 2025, down 181.9% in 2025.
• Over 3 years, Gains from Investment Securities stood at -$837000.0 in 2023, then plunged by 85.19% to -$1.5 million in 2024, then soared by 96.45% to -$55000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$55000.0 (Q4 2025), -$291000.0 (Q3 2025), and -$786000.0 (Q2 2025), per Business Quant data.